Britain and America have signed a significant bilateral deal that will guarantee zero tariffs on British medicine exports entering the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to boost funding on medicines through the NHS. This commitment guarantees that duties on these crucial goods will be held at nothing for a duration of the next three years.
This deal follows recent statements to dramatically increase tariffs on patented drug products, with increases discussed as high as one hundred percent.
"This agreement between the Britain strengthens the worldwide climate for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," a statement said.
Trade Importance
Medicines constitute one of the Britain's biggest goods shipped to the US, which is by far the primary destination for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to September, the UK sold pharmaceutical products worth billions to the US. This figure accounted for nearly one-fifth of total UK exports in that period.
"This guarantee protects employment, increases funding and facilitates the UK to emerge as a international leader for life sciences," a minister remarked.
Key UK Commitments
The deal involves several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds were more than 20%.
Recent Tensions
The pact comes amid a ongoing tension between the drug companies and the British authorities over spending levels and regulatory access.
This friction were heightened by arguments that American customers were charged a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while substantial investments have been announced toward American operations.
One official publicly accepted that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
